ViroPharma Inc. (VPHM) Q2 2012 Earnings Call August 9, 2012 9:00 am ET Executives Vincent J. Milano – Chairman, President and Chief Executive Officer J. Peter Wolf – Vice President, General Counsel and Secretary Charles A Rowland – Vice President, Chief Financial Officer Colin Broom – Vice President and Chief Scientific Officer Daniel B. Soland – Vice President and Chief Operating Officer Analysts Brian Abrahams – Wells Fargo Securities Geoff Meacham – JPMorgan Thomas Wei – Jefferies & Company Rachel McMinn – Bank of America Merrill Lynch Lisa Bayko – JMP Securities Brian Skorney – Brean Murray Mario Corso – Caris & Company Philip Nadeau – Cowen & Company Stephen Willey – Stifel Nicolaus & Company, Inc. Joseph Schwartz – Leerink Swann Llc PresentationOperator
Good morning everyone, and welcome to the ViroPharma Second Quarter 2012 Results Conference Call. Today’s call is being recorded and is expected to last one hour. At this time, I will now turn the call over to ViroPharma’s Chief Executive Officer, Vin Milano. Please go ahead. Vincent J. Milano Thank you, Operator. Good morning, and welcome to everyone joining us on today’s call to discuss our performance for the second quarter of 2012. I’m joined by the other members of the ViroPharma management team, as well as Rich Morris, Will Roberts, and Bob Doody. Before we proceed, Pete Wolf, our General Counsel will provide you of our potential to make forward-looking statements. Pete? J. Peter Wolf Thanks, Vin. During this call, we will make forward-looking statements certain statements such as those regarding our expectations for financial results including guidance, peak year, net sales for Cinryze, peak year European net sales and tax rates, manufacturing capacities, the timing of clinical studies, potential or product candidates and clinical development, changes in channel inventory, our commercial launches of Cinryze, Plenadren and Buccolam in Europe and our ability to continue to identify additional Cinryze patients are examples of such forward looking statements.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.